Quick Answer
X4 Pharmaceuticals, Inc reported R&D Expense of $72.72 million for fiscal year 2025.
X4 Pharmaceuticals, Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $72.72M | -10.9% |
| 2024 | $81.64M | +13.4% |
| 2023 | $72.02M | +17.9% |
| 2022 | $61.06M | +20.6% |
| 2021 | $50.65M | +20.8% |
| 2020 | $41.93M | +39.0% |
| 2019 | $30.16M | +48.3% |
| 2018 | $20.35M | +19.2% |
| 2017 | $17.07M | -4.3% |
| 2016 | $17.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.34M | -9.6% | -5.5% |
| June 30, 2025 | $18.35M | -12.3% | -0.9% |
| March 31, 2025 | $18.51M | -6.8% | -3.4% |
| September 30, 2024 | $19.17M | +0.5% | -8.3% |
| June 30, 2024 | $20.91M | +34.1% | +5.3% |
| March 31, 2024 | $19.85M | -10.0% | +4.1% |
| September 30, 2023 | $19.08M | +35.2% | +22.3% |
| June 30, 2023 | $15.60M | +12.9% | -29.3% |
- X4 Pharmaceuticals, Inc showed a decrease of -10.9% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, X4 Pharmaceuticals, Inc’s r&d expense has grown by 307.8% (from $17.83 million to $72.72 million).
- The most recent figure is from X4 Pharmaceuticals, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: